gene therapy deal
AbbVie’s long-term Rinvoq data shows continued repigmentation in non-segmental vitiligo
The use of Rinvoq in non-segmental vitiligo is under regulatory review by the US FDA
AbbVie’s Rinvoq approved by European Commission for non-segmental vitiligo
Rinvoq is the first and only systemic medication approved in the EU for NSV
AbbVie to acquire Apogee Therapeutics in $10.9bn deal
The acquisition includes clinical-stage candidates for atopic dermatitis and asthma
Allergan Aesthetics launches Skin Quality Index for aesthetic consultations
Spanning four dimensions of skin health, the framework introduces 15 terms and definitions
AbbVie reaches agreement for affordable prescription drugs with US government
The pharma company has also pledged a $100bn investment in US infrastructure over the next decade
Lilly and MeiraGTx partner in $475m ophthalmology deal
The companies will develop and commercialise therapies for genetic conditions
Novo Nordisk reports sales growth in 2025 as R&D pipeline advances
Growth driven by increased sales in diabetes and obesity markets
AbbVie/Genmab’s lymphoma drug shows promise in phase 3 combination trial
Follicular lymphoma affects around 15,000 people in the US every year
AbbVie shares promising phase 3 results for Rinvoq in severe alopecia areata
Around 700,000 people in the US are living with some form of the autoimmune disease
AbbVie’s Elahere granted MHRA approval to treat platinum-resistant ovarian cancer
Approximately 7,500 people are diagnosed with ovarian cancer every year in the UK
Uniphar Rebrands On Demand Business to Uniphar Global Sourcing, Strengthening Global Pharmaceutical Offering
Dublin, Ireland 16th July 2025 – Leading global healthcare services provider, Uniphar, has launched Uniphar | Global Sourcing, a new identity for its On Demand business that strengthens its position...
AbbVie gains rights to IGI’s phase 1 trispecific engager in deal worth over $1.9bn
ISB 2001 is in early-stage clinical development for relapsed/refractory multiple myeloma